DOP53: Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term ExtensionECCO'24 Stockholm 2024
DOP54: Guselkumab and golimumab combination induction therapy in Ulcerative Colitis results in early local tissue healing that is sustained through guselkumab maintenance therapyECCO'24 Stockholm 2024
DOP55: High diagnostic accuracy of 4-probe methylation biomarkers in paediatric Inflammatory Bowel Disease by epigenome-wide analysisECCO'24 Stockholm 2024
DOP56: Fibrosis-related transcriptome unveils a distinctive matrix remodelling pattern in penetrating but not in stricturing ileal Crohn's DiseaseECCO'24 Stockholm 2024
DOP57: Cystic fibrosis risk variants confer a protective effect against Inflammatory Bowel Disease in large-scale exome sequencing analysisECCO'24 Stockholm 2024
DOP58: Human Leukocyte Antigen drives methylation signatures in primary sclerosing cholangitis but not in IgG4-related sclerosing cholangitis.ECCO'24 Stockholm 2024
DOP60: Prevalence of undiagnosed inflammatory Bowel Disease in patients with spondyloarthritis: EISER StudyECCO'24 Stockholm 2024
DOP61: Up-regulated Gremlin 1 in fibroblasts from Crohn’s Disease fibrotic strictures: A potential therapeutic targetECCO'24 Stockholm 2024
DOP62: A core molecular resistome characterised by extracellular matrix dysregulation and neutrophil degranulation predicts resistance to multiple therapies in Ulcerative ColitisECCO'24 Stockholm 2024
DOP63: Mortality in Pediatric-onset Immune-Mediated Inflammatory Disease – A Nationwide Study.ECCO'24 Stockholm 2024
DOP64: Steroid-sparing effect of risankizumab vs ustekinumab in patients with moderately to severely active Crohn’s Disease: Post hoc results from the phase 3b SEQUENCE trialECCO'24 Stockholm 2024
DOP66: INSPIRE: Preliminary data from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn’s Disease and complex perianal fistulasECCO'24 Stockholm 2024
DOP67: MB310: From Clinical FMT to a Phase 1 Study with a Defined, Orally Administered Live Bacterial Therapeutic for Mild Moderate Ulcerative ColitisECCO'24 Stockholm 2024
DOP69: Longitudinal gut microbiome dynamics in relation to disease flares in Inflammatory Bowel Disease, pilot data from the IBD-Tracker studyECCO'24 Stockholm 2024
DOP70: Prevalence and severity of bowel urgency in Crohn’s Disease: Results from the Communicating Needs and Features of IBD Experience (CONFIDE) SurveyECCO'24 Stockholm 2024